Atlas Brown Inc. Has $1.61 Million Stock Holdings in Humana Inc. (NYSE:HUM)

Atlas Brown Inc. increased its position in Humana Inc. (NYSE:HUM) by 0.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,352 shares of the insurance provider’s stock after purchasing an additional 38 shares during the quarter. Atlas Brown Inc.’s holdings in Humana were worth $1,611,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Creative Financial Designs Inc. ADV grew its position in shares of Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after buying an additional 61 shares during the period. Atwood & Palmer Inc. bought a new position in Humana in the third quarter valued at approximately $29,000. Ashton Thomas Securities LLC acquired a new stake in Humana during the 3rd quarter worth $31,000. Your Advocates Ltd. LLP raised its position in shares of Humana by 81.8% during the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares during the last quarter. Finally, Hollencrest Capital Management acquired a new position in shares of Humana in the 2nd quarter valued at $40,000. 92.38% of the stock is owned by institutional investors.

Humana Stock Up 0.6 %

Humana stock traded up $1.63 during mid-day trading on Friday, reaching $269.76. The company’s stock had a trading volume of 1,146,763 shares, compared to its average volume of 1,146,409. The business’s 50 day simple moving average is $273.07 and its 200 day simple moving average is $311.56. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $459.76. The company has a market capitalization of $32.48 billion, a price-to-earnings ratio of 23.89, a price-to-earnings-growth ratio of 2.12 and a beta of 0.55.

Humana (NYSE:HUM) last released its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The business had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. As a group, research analysts anticipate that Humana Inc. will post 16.14 earnings per share for the current year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a $0.885 dividend. The ex-dividend date is Tuesday, December 31st. This represents a $3.54 annualized dividend and a dividend yield of 1.31%. Humana’s dividend payout ratio is presently 31.36%.

Insider Buying and Selling

In other news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.32% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on HUM shares. Piper Sandler downgraded Humana from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $392.00 to $274.00 in a report on Thursday, October 3rd. Jefferies Financial Group downgraded shares of Humana from a “buy” rating to a “hold” rating and cut their price target for the company from $519.00 to $253.00 in a research report on Monday, October 7th. KeyCorp started coverage on shares of Humana in a report on Friday, October 11th. They set a “sector weight” rating for the company. Stephens reaffirmed an “equal weight” rating and issued a $250.00 target price on shares of Humana in a research note on Wednesday, October 9th. Finally, Morgan Stanley upped their price objective on shares of Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 17th. Twenty investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $302.00.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.